Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Interventional Antibiotic Treatment Replacing Antibiotic Prophylaxis during Allogeneic Hematopoietic Stem Cell Transplantation Is Safe and Feasible: A Single-Center Analysis

Rosa Toenges, Fabian Lang, Rakhshinda Ghaffar, Vera Schlipfenbacher, Julia Riemann, Salem Ajib, Khouloud Kouidri, Anjali Cremer, Weber Bodo, Thu Nguyen, Antje Knoch, Janne Vehreschild, Hubert Serve, Gesine Bug

Blood (2022) 140 (Supplement 1): 10478–10479.

https://doi.org/10.1182/blood-2022-163303

Published: 2022

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Zack Pemberton-Whiteley, Jorge E. Cortes, Joannie Clements, Cristina Ruiz, Delphine Rea, Lisa Machado, Fabian Lang, Naoto Takahashi, Nigel Deekes, Sung-Ho Moon, Andrew Grigg, Merula Steagall, Cornelia Borowczak, Virginia Pilipovic, Pauline Frank, Cristina Constantinescu, Carla Boquimpani

Blood (2021) 138 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2021-147739

Published: 2021

Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Blood (2020) 136 (Supplement 1): 47–50.

https://doi.org/10.1182/blood-2020-139677

Published: 2020

Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD

Blood (2018) 132 (Supplement 1): 792.

https://doi.org/10.1182/blood-2018-99-113609

Published: 2018

Journal Articles

Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

Blood (2018) 132 (Supplement 1): 661.

https://doi.org/10.1182/blood-2018-99-112614

Published: 2018

Journal Articles

Impact of Donor Chimerism-Guided Immunomodulation after Allogeneic Stem Cell Transplant on the Outcome of Patients with AML and MDS

Juliane Steinmann, Sarah Lindner, MD, Zuzana Jedlickova, MD, Salem Ajib, MD, Saskia C. Gueller, MD, Tobias Berg, MD, Julia Riemann, MD, Fabian Lang, MD, Rosa Toenges, MD, Hans Martin, MD, Michael Kramer, M.Sc., Johannes Schetelig, MD MSc, Hubert Serve, MD, Christian Thiede, MD, Gesine Bug

Blood (2018) 132 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2018-99-116088

Published: 2018

Journal Articles

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Blood (2018) 131 (13): 1464–1475.

https://doi.org/10.1182/blood-2017-07-796862

Published: 2018

Includes: Supplemental data

Journal Articles

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Hans Michael Kvasnicka, Gina Liviana Frank, Marlene Lemp, Fabian Lang, MD, Juergen Thiele, MD

Blood (2017) 130 (Supplement 1): 2913.

https://doi.org/10.1182/blood.V130.Suppl_1.2913.2913

Published: 2017

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry

Andrea Kaifie, MD, Susanne Isfort, MD, Dominik Wolf, MD, Mathias Hanel, MD, Christoph Maintz, MD, Norbert Gattermann, MD PhD, Uwe Platzbecker, MD, Eray Goekkurt, MD, Ina Boeters, MD, Richard Hansen, MD, Fabian Lang, MD, Joachim R. Goethert, Karla Bennemann, MD, Christoph Rollig, MD MSC, Hubert Serve, MD, Wolfgang E Berdel, MD, Gerhard Ehninger, MD, Tim H Bruemmendorf, MD, Steffen Koschmieder, MD

Blood (2014) 124 (21): 5561.

https://doi.org/10.1182/blood.V124.21.5561.5561

Published: 2014

Journal Articles

Functional Analysis of the Subclonal Architecture of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) at a Single Cell Level

Bartosch Wojcik, Fabian Lang, MD, Susanne Badura, Anja Vogel, Tamara Tesanovic, Thomas Oellerich, Timm Schroeder, PhD, J.H. Frederik Falkenburg, Monika Brüggemann, Oliver G. Ottmann, MD, Michael A. Rieger, PhD

Blood (2014) 124 (21): 3778.

https://doi.org/10.1182/blood.V124.21.3778.3778

Published: 2014

Journal Articles

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Lydia Wunderle, MD, Susanne Badura, Fabian Lang, MD, Andrea Wolf, Eberhard Schleyer, MD, Hubert Serve, MD, Nicola Goekbuget, MD, Heike Pfeifer, MD, Gesine Bug, MD, PhD, Oliver G. Ottmann, MD

Blood (2013) 122 (21): 2675.

https://doi.org/10.1182/blood.V122.21.2675.2675

Published: 2013

Journal Articles

In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission

Heike Pfeifer, MD, Katharina Raum, Sandra Markovic, Stephanie Fey, Julia Obländer, Verena Nowak, Wunderle Lydia, MD, Fabian Lang, MD, Dieter Hoelzer, MD, Wolf-Karsten Hofmann, MD, Nicola Goekbuget, MD, Oliver G. Ottmann, MD, Daniel Nowak, MD

Blood (2013) 122 (21): 231.

https://doi.org/10.1182/blood.V122.21.231.231

Published: 2013

Journal Articles

Modulation of Leukemic Stem Cell Self-Renewal and Cell Fate Decisions by Inhibition of Hedgehog Signalling in Human Acute Lymphoblastic Leukemia (ALL).

Fabian Lang, MD, Susanne Badura, Martin Ruthardt, MD, Michael A. Rieger, Oliver G. Ottmann, MD

Blood (2012) 120 (21): 2578.

https://doi.org/10.1182/blood.V120.21.2578.2578

Published: 2012

NARROW

Interventional Antibiotic Treatment Replacing Antibiotic Prophylaxis during Allogeneic Hematopoietic Stem Cell Transplantation Is Safe and Feasible: A Single-Center Analysis

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

Impact of Donor Chimerism-Guided Immunomodulation after Allogeneic Stem Cell Transplant on the Outcome of Patients with AML and MDS

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry

Functional Analysis of the Subclonal Architecture of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) at a Single Cell Level

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission

Modulation of Leukemic Stem Cell Self-Renewal and Cell Fate Decisions by Inhibition of Hedgehog Signalling in Human Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only